Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Reverse causality behind the association between reproductive history and MS.
Acute and subacute inflammation of the optic nerve and its sheath: clinical features in Chinese patients.
In vivo detection of experimental optic neuritis by pupillometry.
The elusive biomarker for personalized medicine in multiple sclerosis: The search continues.
The axes of access--improving care for patients with disabilities.
UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production.
Mimics and chameleons of optic neuritis.
RORγt, but not T-bet, overexpression exacerbates an autoimmune model for multiple sclerosis.
New Microparticle Secondary Progressive MS Therapy Dosing Tested In Australian Clinical Trial
FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.
Factors affecting anxiety in multiple sclerosis.
The effects of bortezomib on the immune system: a focus on immune regulation.
The Management of Pediatric Multiple Sclerosis.
Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis.
Headache and neurological disease in pregnancy.
Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis.
Proteomic analysis of the cerebrospinal fluid in multiple sclerosis and neuromyelitis optica patients.
Evidence against the Involvement of Chronic Cerebrospinal Venous Abnormalities in Multiple Sclerosis. A Case-Control Study.
Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study.
Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
Multiple sclerosis fatigue relief by bilateral somatosensory cortex neuromodulation.
FTY720 protects neuronal cells from damage induced by human prion protein by inactivating the JNK pathway.
Alemtuzumab for multiple sclerosis: who and when to treat?
Coordinated control of oligodendrocyte development by extrinsic and intrinsic signaling cues.

Pages